Remaining Compound. On the completion or termination of the Study, Syndax shall ensure that all unused Genentech Compound, as well as all used and unused vials and bottles containing (or that contained) the Genentech Compound, are destroyed in accordance with Syndax’s standard operating procedures and documented accordingly (including certifying such destruction in writing to Genentech), or returned to Genentech or its designated agent if Syndax is unable to properly destroy the Genentech Compound, vials or bottles.
Appears in 3 contracts
Sources: Combination Study Collaboration Agreement (Syndax Pharmaceuticals Inc), Combination Study Collaboration Agreement (Syndax Pharmaceuticals Inc), Combination Study Collaboration Agreement (Syndax Pharmaceuticals Inc)